Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytodiagnosis | 4 | 2018 | 224 | 1.150 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 2317 | 0.900 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2018 | 699 | 0.750 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 127 | 0.720 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 2341 | 0.680 |
Why?
|
| Specimen Handling | 2 | 2018 | 304 | 0.670 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2012 | 157 | 0.560 |
Why?
|
| Laser Capture Microdissection | 2 | 2012 | 40 | 0.530 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 11817 | 0.510 |
Why?
|
| Cushing Syndrome | 1 | 2014 | 72 | 0.470 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1929 | 0.410 |
Why?
|
| Papillomaviridae | 1 | 2014 | 629 | 0.380 |
Why?
|
| Thymoma | 1 | 2014 | 250 | 0.380 |
Why?
|
| Precision Medicine | 1 | 2018 | 1201 | 0.360 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 7704 | 0.350 |
Why?
|
| Thymus Neoplasms | 1 | 2014 | 413 | 0.340 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 734 | 0.310 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 10627 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2506 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2014 | 424 | 0.290 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3698 | 0.280 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 16053 | 0.270 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 1013 | 0.270 |
Why?
|
| Neoplasms | 6 | 2018 | 15710 | 0.260 |
Why?
|
| Adenocarcinoma | 5 | 2015 | 7908 | 0.260 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2006 | 94 | 0.260 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2006 | 132 | 0.250 |
Why?
|
| T-Box Domain Proteins | 1 | 2006 | 163 | 0.250 |
Why?
|
| Caenorhabditis elegans | 1 | 2006 | 270 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 3 | 2022 | 2617 | 0.220 |
Why?
|
| Gene Amplification | 3 | 2014 | 745 | 0.220 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 84 | 0.220 |
Why?
|
| S100 Proteins | 1 | 2013 | 184 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 342 | 0.200 |
Why?
|
| Pathologists | 1 | 2021 | 99 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 4076 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5531 | 0.160 |
Why?
|
| Centrifugation | 1 | 2018 | 65 | 0.160 |
Why?
|
| Mutation | 7 | 2015 | 15642 | 0.150 |
Why?
|
| Humans | 22 | 2024 | 270843 | 0.150 |
Why?
|
| Tissue Embedding | 1 | 2015 | 29 | 0.130 |
Why?
|
| Sampling Studies | 1 | 2015 | 173 | 0.130 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2014 | 18 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2014 | 159 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2007 | 840 | 0.120 |
Why?
|
| F-Box Proteins | 1 | 2014 | 102 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 111 | 0.110 |
Why?
|
| Hematoxylin | 1 | 2012 | 34 | 0.110 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2012 | 51 | 0.110 |
Why?
|
| Lung | 1 | 2024 | 3245 | 0.110 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2012 | 44 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2014 | 674 | 0.100 |
Why?
|
| Automation | 1 | 2012 | 152 | 0.100 |
Why?
|
| Prognosis | 6 | 2015 | 22249 | 0.100 |
Why?
|
| Gastrectomy | 1 | 2015 | 479 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1395 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1183 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 4862 | 0.090 |
Why?
|
| Genomics | 1 | 2021 | 2819 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 620 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 4452 | 0.090 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 1415 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 5123 | 0.080 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 124 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 5242 | 0.080 |
Why?
|
| Proteins | 1 | 2007 | 1989 | 0.080 |
Why?
|
| Female | 11 | 2022 | 147292 | 0.080 |
Why?
|
| Amphotericin B | 1 | 2010 | 293 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 867 | 0.080 |
Why?
|
| Mucormycosis | 1 | 2010 | 110 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 5031 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2015 | 835 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2122 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 2010 | 207 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 2319 | 0.080 |
Why?
|
| ras Proteins | 1 | 2011 | 783 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 1228 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1560 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4730 | 0.070 |
Why?
|
| Embryonic Induction | 1 | 2006 | 57 | 0.070 |
Why?
|
| Blastomeres | 1 | 2006 | 24 | 0.070 |
Why?
|
| Pharyngeal Muscles | 1 | 2006 | 37 | 0.070 |
Why?
|
| Melanoma | 1 | 2013 | 5445 | 0.070 |
Why?
|
| Male | 8 | 2015 | 127630 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 4925 | 0.060 |
Why?
|
| DNA | 1 | 2013 | 2745 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2100 | 0.060 |
Why?
|
| Adult | 7 | 2015 | 80709 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3033 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2010 | 854 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2011 | 2329 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2006 | 705 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 2560 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 2341 | 0.050 |
Why?
|
| Phenotype | 1 | 2014 | 6404 | 0.050 |
Why?
|
| Young Adult | 3 | 2015 | 22140 | 0.050 |
Why?
|
| Aged | 7 | 2015 | 72902 | 0.050 |
Why?
|
| Binding Sites | 1 | 2006 | 2210 | 0.050 |
Why?
|
| Middle Aged | 8 | 2015 | 89535 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 611 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 3385 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 3241 | 0.050 |
Why?
|
| Risk Factors | 2 | 2015 | 18267 | 0.050 |
Why?
|
| Epithelium | 1 | 2012 | 729 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1808 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 2223 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 5466 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 4895 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2015 | 13882 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2012 | 5362 | 0.040 |
Why?
|
| Cattle | 1 | 2007 | 792 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 1006 | 0.030 |
Why?
|
| Dogs | 1 | 2007 | 1174 | 0.030 |
Why?
|
| DNA Primers | 1 | 2007 | 1422 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2014 | 84 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 5239 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6245 | 0.030 |
Why?
|
| Texas | 2 | 2014 | 6460 | 0.030 |
Why?
|
| Maryland | 1 | 2011 | 50 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2014 | 9324 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14506 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2015 | 555 | 0.020 |
Why?
|
| Survival Rate | 2 | 2015 | 12451 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 283 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 4281 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 3666 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 4932 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 3109 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6127 | 0.020 |
Why?
|
| Empyema, Pleural | 1 | 2010 | 48 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 15198 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2260 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 691 | 0.020 |
Why?
|
| Animals | 2 | 2007 | 61014 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2520 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3238 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 2364 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1538 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1377 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 3399 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2379 | 0.010 |
Why?
|
| Adolescent | 2 | 2014 | 32336 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 30813 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2014 | 34238 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6196 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 13266 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16792 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 35331 | 0.010 |
Why?
|
| Child | 1 | 2014 | 30200 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2014 | 39512 | 0.010 |
Why?
|